CN109324190A - 高通量受体:配体鉴定方法 - Google Patents
高通量受体:配体鉴定方法 Download PDFInfo
- Publication number
- CN109324190A CN109324190A CN201811139644.3A CN201811139644A CN109324190A CN 109324190 A CN109324190 A CN 109324190A CN 201811139644 A CN201811139644 A CN 201811139644A CN 109324190 A CN109324190 A CN 109324190A
- Authority
- CN
- China
- Prior art keywords
- cell
- protein
- peptide
- expression
- albumen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 200
- 238000000034 method Methods 0.000 title abstract description 131
- 210000004027 cell Anatomy 0.000 claims description 768
- 108090000623 proteins and genes Proteins 0.000 claims description 432
- 102000004169 proteins and genes Human genes 0.000 claims description 424
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 claims description 363
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 277
- 230000014509 gene expression Effects 0.000 claims description 249
- 238000002493 microarray Methods 0.000 claims description 138
- 239000000725 suspension Substances 0.000 claims description 97
- 102000005962 receptors Human genes 0.000 claims description 73
- 108020003175 receptors Proteins 0.000 claims description 73
- 210000000805 cytoplasm Anatomy 0.000 claims description 54
- 239000002773 nucleotide Substances 0.000 claims description 50
- 125000003729 nucleotide group Chemical group 0.000 claims description 50
- 239000007787 solid Substances 0.000 claims description 41
- 239000011325 microbead Substances 0.000 claims description 28
- 235000013601 eggs Nutrition 0.000 claims description 25
- 230000035772 mutation Effects 0.000 claims description 24
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 125000000539 amino acid group Chemical group 0.000 claims description 11
- 210000004899 c-terminal region Anatomy 0.000 claims description 11
- 230000008859 change Effects 0.000 claims description 8
- 238000007667 floating Methods 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims 1
- 230000003993 interaction Effects 0.000 abstract description 69
- 235000018102 proteins Nutrition 0.000 description 366
- 108010074708 B7-H1 Antigen Proteins 0.000 description 68
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 68
- 239000005090 green fluorescent protein Substances 0.000 description 66
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 63
- 150000001875 compounds Chemical class 0.000 description 44
- 108091058545 Secretory proteins Proteins 0.000 description 30
- 102000040739 Secretory proteins Human genes 0.000 description 30
- 108091006047 fluorescent proteins Proteins 0.000 description 30
- 102000034287 fluorescent proteins Human genes 0.000 description 30
- 230000004927 fusion Effects 0.000 description 30
- 239000000523 sample Substances 0.000 description 28
- 108020001507 fusion proteins Proteins 0.000 description 22
- 102000037865 fusion proteins Human genes 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 19
- 210000004962 mammalian cell Anatomy 0.000 description 17
- 230000028327 secretion Effects 0.000 description 17
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 16
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 16
- 210000000170 cell membrane Anatomy 0.000 description 15
- 238000001890 transfection Methods 0.000 description 15
- 239000005482 chemotactic factor Substances 0.000 description 14
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 238000004064 recycling Methods 0.000 description 13
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 12
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 12
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 102000027257 transmembrane receptors Human genes 0.000 description 12
- 108091008578 transmembrane receptors Proteins 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 11
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 11
- 239000011521 glass Substances 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 10
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 10
- 229940045513 CTLA4 antagonist Drugs 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 10
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 10
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 10
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 102000016359 Fibronectins Human genes 0.000 description 9
- 238000012350 deep sequencing Methods 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- 102000015696 Interleukins Human genes 0.000 description 8
- 102000018697 Membrane Proteins Human genes 0.000 description 8
- 108010052285 Membrane Proteins Proteins 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229940047122 interleukins Drugs 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000011324 bead Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 108010093036 interleukin receptors Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 108010009202 Growth Factor Receptors Proteins 0.000 description 6
- 102000009465 Growth Factor Receptors Human genes 0.000 description 6
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 6
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 102000006240 membrane receptors Human genes 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000010474 transient expression Effects 0.000 description 6
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 5
- 108010000912 Egg Proteins Proteins 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 5
- 108010067306 Fibronectins Proteins 0.000 description 5
- 102000006830 Luminescent Proteins Human genes 0.000 description 5
- 108010047357 Luminescent Proteins Proteins 0.000 description 5
- 102000003939 Membrane transport proteins Human genes 0.000 description 5
- 108090000301 Membrane transport proteins Proteins 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 235000014103 egg white Nutrition 0.000 description 5
- 210000000969 egg white Anatomy 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 230000004907 flux Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000012775 microarray technology Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108091093088 Amplicon Proteins 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 108010001857 Cell Surface Receptors Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000004940 costimulation Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 101710153593 Albumin A Proteins 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 3
- 102100034980 ICOS ligand Human genes 0.000 description 3
- 102100025292 Stress-induced-phosphoprotein 1 Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000010399 physical interaction Effects 0.000 description 3
- 230000004850 protein–protein interaction Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000003146 transient transfection Methods 0.000 description 3
- 102000035160 transmembrane proteins Human genes 0.000 description 3
- 108091005703 transmembrane proteins Proteins 0.000 description 3
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 108700020490 Drosophila S Proteins 0.000 description 2
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229960005347 belatacept Drugs 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000428 immunological synapse Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000007885 magnetic separation Methods 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229940035567 orencia Drugs 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 108010084420 scavidin Proteins 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004555 Butyrophilins Human genes 0.000 description 1
- 108010017533 Butyrophilins Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 241001454374 Drosophila <fruit fly, subgenus> Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000027583 GPCRs class C Human genes 0.000 description 1
- 108091008882 GPCRs class C Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 206010025671 Malignant melanoma stage IV Diseases 0.000 description 1
- 101001117316 Mus musculus Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101001117311 Mus musculus Programmed cell death 1 ligand 2 Proteins 0.000 description 1
- 102000002356 Nectin Human genes 0.000 description 1
- 108060005251 Nectin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 101710184528 Scaffolding protein Proteins 0.000 description 1
- 241001282153 Scopelogadus mizolepis Species 0.000 description 1
- 230000020385 T cell costimulation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000003920 environmental process Methods 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- -1 fluorescin Compound Chemical class 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000007514 turning Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261735791P | 2012-12-11 | 2012-12-11 | |
| US61/735,791 | 2012-12-11 | ||
| US201361833588P | 2013-06-11 | 2013-06-11 | |
| US61/833,588 | 2013-06-11 | ||
| CN201380071758.8A CN105121715B (zh) | 2012-12-11 | 2013-12-05 | 高通量受体:配体鉴定方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380071758.8A Division CN105121715B (zh) | 2012-12-11 | 2013-12-05 | 高通量受体:配体鉴定方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109324190A true CN109324190A (zh) | 2019-02-12 |
Family
ID=50934838
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811139644.3A Pending CN109324190A (zh) | 2012-12-11 | 2013-12-05 | 高通量受体:配体鉴定方法 |
| CN201380071758.8A Expired - Fee Related CN105121715B (zh) | 2012-12-11 | 2013-12-05 | 高通量受体:配体鉴定方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380071758.8A Expired - Fee Related CN105121715B (zh) | 2012-12-11 | 2013-12-05 | 高通量受体:配体鉴定方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10048271B2 (https=) |
| EP (2) | EP3640375A3 (https=) |
| JP (2) | JP2016500255A (https=) |
| KR (1) | KR102208505B1 (https=) |
| CN (2) | CN109324190A (https=) |
| AU (2) | AU2013359907B2 (https=) |
| BR (1) | BR112015013557B1 (https=) |
| CA (1) | CA2894511C (https=) |
| IL (2) | IL239096B (https=) |
| SG (2) | SG11201504558TA (https=) |
| WO (1) | WO2014093118A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3640375A3 (en) | 2012-12-11 | 2020-07-29 | Albert Einstein College of Medicine | Methods for high throughput receptor/ligand identification |
| CA2954360C (en) | 2014-07-07 | 2022-11-22 | Johan ELF | Phenotypic characterization and in situ genotyping of a library of genetically different cells |
| KR20190044029A (ko) * | 2016-05-18 | 2019-04-29 | 알버트 아인슈타인 컬리지 오브 메디슨, 인크. | 변이체 pd-l1 폴리펩타이드, t-세포 조절 다량체 폴리펩타이드 및 이들의 사용 방법 |
| CA3019005A1 (en) | 2016-05-18 | 2017-11-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| JP7019171B2 (ja) * | 2016-11-24 | 2022-02-15 | 国立研究開発法人物質・材料研究機構 | 細胞表面に存在する分子の結合による細胞間相互作用を計測する方法 |
| WO2018111941A1 (en) * | 2016-12-12 | 2018-06-21 | 13.8, Inc. | Compositions of high affinity reagents and methods of use thereof |
| CN116970059A (zh) | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| IL269000B2 (en) | 2017-03-15 | 2024-06-01 | Cue Biopharma Inc | Methods for modulating an immune response |
| TW201920249A (zh) | 2017-09-07 | 2019-06-01 | 美商信號生物製藥公司 | 具有結合位點之t細胞調節多聚體多肽及其使用方法 |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2021219807A1 (en) * | 2020-04-30 | 2021-11-04 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Pd-l1 variants with improved affinity towards pd-1 |
| TW202208395A (zh) | 2020-05-12 | 2022-03-01 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| EP4211149A4 (en) | 2020-09-09 | 2024-10-09 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050009012A1 (en) * | 2001-01-25 | 2005-01-13 | Large Scale Biology Corporation | Cytoplasmic inhibition of gene expression and expression of a foreign protein in a monocot plant by a plant viral vector |
| US20080269070A1 (en) * | 2007-04-27 | 2008-10-30 | Dow Global Technologies, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| CN101384621A (zh) * | 2005-11-10 | 2009-03-11 | 受体生物公司 | 产生受体和配体同种型的方法 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635363A (en) | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
| US5869270A (en) | 1996-01-31 | 1999-02-09 | Sunol Molecular Corporation | Single chain MHC complexes and uses thereof |
| US6211342B1 (en) | 1996-07-18 | 2001-04-03 | Children's Hospital Medical Center | Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function |
| US20050003431A1 (en) | 1996-08-16 | 2005-01-06 | Wucherpfennig Kai W. | Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor |
| EP0979239B1 (en) | 1997-02-13 | 2006-10-18 | The Regents Of The University Of California | Prevention and treatment of hepatocellular cancer |
| US7098306B2 (en) | 1997-02-13 | 2006-08-29 | The Regents Of The University Of California | Method and compositions for treating hepatocellular cancer |
| US6268411B1 (en) | 1997-09-11 | 2001-07-31 | The Johns Hopkins University | Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
| US20030007978A1 (en) | 1997-09-16 | 2003-01-09 | Burrows Gregory G. | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| US6696304B1 (en) * | 1999-02-24 | 2004-02-24 | Luminex Corporation | Particulate solid phase immobilized protein quantitation |
| KR100903710B1 (ko) | 1999-04-30 | 2009-06-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 돌연변이체 인간 ｃｄ80, 이를 포함하는 조성물, 및 이를제조하고 이용하는 방법 |
| US20020006664A1 (en) | 1999-09-17 | 2002-01-17 | Sabatini David M. | Arrayed transfection method and uses related thereto |
| CA2410642A1 (en) | 2000-05-25 | 2001-11-29 | Sunol Molecular Corporation | Modulation of t-cell receptor interactions |
| WO2004029197A2 (en) | 2001-06-22 | 2004-04-08 | Maxygen, Inc. | Co-stimulatory molecules |
| US20020122820A1 (en) | 2001-01-16 | 2002-09-05 | Hildebrand William H. | Soluble MHC artificial antigen presenting cells |
| ES2747357T3 (es) | 2001-03-14 | 2020-03-10 | Dako Denmark As | Construcciones de moléculas MHC y sus usos para el diagnóstico y terapia |
| WO2002093129A2 (en) * | 2001-05-15 | 2002-11-21 | University Of Medicine & Dentistry Of New Jersey | Methods for analyzing interactions between proteins in live and intact cells |
| WO2002099070A2 (en) | 2001-06-04 | 2002-12-12 | Corixa Corporation | Compositions and methods for high-level, large-scale production of recombinant proteins |
| US20030017134A1 (en) | 2001-06-19 | 2003-01-23 | Technion Research And Development Foundation Ltd. | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
| WO2003006632A2 (en) | 2001-07-12 | 2003-01-23 | Canvac | Methods and compisitions for activation human t cells in vitro |
| US20040038349A1 (en) | 2001-07-27 | 2004-02-26 | Hilbert David M. | Heteromultimeric TNF ligand family members |
| PT1454138E (pt) | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| US8895020B2 (en) | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| US7432351B1 (en) | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
| WO2004076488A1 (en) | 2003-02-27 | 2004-09-10 | Theravision Gmbh | A molecule which binds cd80 and cd86 |
| AU2003901876A0 (en) | 2003-04-17 | 2003-05-08 | The Macfarlane Burnet Institute For Medical Research And Public Health | Viral vector |
| US20050042641A1 (en) | 2003-05-27 | 2005-02-24 | Cold Spring Harbor Laboratory | In vivo high throughput selection of RNAi probes |
| US7470513B2 (en) | 2003-11-10 | 2008-12-30 | Academia Sinica | Risk assessment for adverse drug reactions |
| BRPI0508470A (pt) | 2004-03-05 | 2007-07-31 | Chiron Corp | sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos |
| DE102004014983A1 (de) | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
| AU2005247950B2 (en) | 2004-05-27 | 2012-02-02 | Receptor Logic, Inc. | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| US8518697B2 (en) | 2006-04-04 | 2013-08-27 | Washington University | Single chain trimers and uses therefor |
| US7977457B2 (en) | 2006-05-19 | 2011-07-12 | Teva Pharmaceutical Industries Ltd. | Fusion proteins, uses thereof and processes for producing same |
| EP1889851A1 (en) | 2006-08-18 | 2008-02-20 | Charite Universitätsmedizin-Berlin | PAX2 and PAX8 as targets for immunologic and molecular tumour treatment strategies |
| US8992937B2 (en) | 2006-08-28 | 2015-03-31 | Washington University | Disulfide trap MHC class I molecules and uses therefor |
| CA2670658A1 (en) | 2006-12-28 | 2008-07-10 | International Institute Of Cancer Immunology, Inc. | Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same |
| EP2129389B1 (en) | 2007-02-15 | 2014-10-08 | MannKind Corporation | A method for enhancing t cell response |
| EP2361930A3 (en) | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases |
| US8926961B2 (en) | 2007-10-03 | 2015-01-06 | Board Of Trustees Of The University Of Arkansas | HPV E6 protein T cell epitopes and uses thereof |
| CN101418309B (zh) | 2007-10-23 | 2011-05-04 | 中国农业科学院上海兽医研究所 | 柔嫩艾美耳球虫蛋白质二硫键异构酶基因的克隆、表达及应用 |
| DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| EP2184070A1 (en) | 2008-11-07 | 2010-05-12 | Hla-G Technologies | HLA-G proteins and pharmaceutical uses thereof |
| CA2748314C (en) | 2009-02-03 | 2018-10-02 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
| EP2445935B1 (en) | 2009-06-25 | 2015-07-01 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Multimeric polypeptides of hla-g including alpha1-alpha3 monomers and pharmaceutical uses thereof |
| WO2011066342A2 (en) * | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| NZ628923A (en) * | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| CN107880136B (zh) | 2010-09-21 | 2021-11-12 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| US9428567B2 (en) | 2010-12-22 | 2016-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Antagonists of interleukin-2 receptor |
| WO2012127464A2 (en) | 2011-03-23 | 2012-09-27 | Gavish-Galilee Bio Applications Ltd | Constitutively activated t cells for use in adoptive cell therapy |
| EA201400046A1 (ru) | 2011-06-22 | 2014-07-30 | Ф. Хоффманн-Ля Рош Аг | Удаление клеток-мишеней с помощью циркулирующих вирусспецифических цитотоксических т-клеток с использованием содержащих гкгс класса i комплексов |
| MY180616A (en) | 2011-06-30 | 2020-12-03 | Genzyme Corp | Inhibitors of t-cell activation |
| US9494588B2 (en) | 2011-08-30 | 2016-11-15 | Jacobs University Bremen Ggmbh | Gene coded for a MHC class I molecule, plasmid, expression system protein, multimer, reagent and kit to analyze a T cell frequency |
| US8956619B2 (en) | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| HRP20201595T1 (hr) * | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| CA2861206C (en) | 2012-01-13 | 2021-07-06 | Richard J. O'reilly | Immunogenic wt-1 peptides and methods of use thereof |
| CA2863658C (en) | 2012-02-03 | 2023-03-14 | Emory University | Immunostimulatory compositions, particles, and uses related thereto |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| JP2015537043A (ja) | 2012-11-30 | 2015-12-24 | ロシュ グリクアート アーゲー | 多機能タンパク質を含むがん細胞標的化ｍｈｃクラスｉを用いた循環性ウイルス特異的細胞傷害性ｔ細胞によるがん細胞の除去 |
| EP3640375A3 (en) | 2012-12-11 | 2020-07-29 | Albert Einstein College of Medicine | Methods for high throughput receptor/ligand identification |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| MY171854A (en) | 2013-03-29 | 2019-11-05 | Sumitomo Dainippon Pharma Co Ltd | Wt1 antigen peptide conjugate vaccine |
| GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| SG11201605632SA (en) | 2014-01-21 | 2016-08-30 | Einstein Coll Med | Cellular platform for rapid and comprehensive t-cell immunomonitoring |
| US20160152725A1 (en) | 2014-02-25 | 2016-06-02 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide |
| EP3112378B1 (en) | 2014-02-26 | 2020-06-24 | Tella, Inc. | Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide |
| WO2015164815A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| PL3157552T3 (pl) | 2014-06-18 | 2020-05-18 | Albert Einstein College Of Medicine | Polipeptydy syntac i ich zastosowania |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| GB2538666A (en) | 2014-07-21 | 2016-11-23 | Delinia Inc | Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases |
| JP6800141B2 (ja) | 2014-08-12 | 2020-12-16 | マサチューセッツ インスティテュート オブ テクノロジー | Ｉｌ−２およびインテグリン結合性ｆｃ融合タンパク質による相乗的な腫瘍処置 |
| WO2016029043A1 (en) | 2014-08-21 | 2016-02-25 | The General Hospital Corporation | Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same |
| MY193723A (en) | 2014-08-29 | 2022-10-27 | Hoffmann La Roche | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 |
| EP3283508B1 (en) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| EP3328377A4 (en) | 2015-07-31 | 2019-03-13 | Tarveda Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR IMMUNE ONCOLOGY THERAPIES |
| CN106565836B (zh) | 2015-10-10 | 2020-08-18 | 中国科学院广州生物医药与健康研究院 | 高亲和力的可溶性pdl-1分子 |
| CA3014458A1 (en) | 2016-03-02 | 2017-09-08 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| AU2017225787B2 (en) | 2016-03-03 | 2021-09-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| KR102687530B1 (ko) | 2016-05-04 | 2024-07-25 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| KR20190044029A (ko) | 2016-05-18 | 2019-04-29 | 알버트 아인슈타인 컬리지 오브 메디슨, 인크. | 변이체 pd-l1 폴리펩타이드, t-세포 조절 다량체 폴리펩타이드 및 이들의 사용 방법 |
| TW201925235A (zh) | 2017-09-07 | 2019-07-01 | 美商信號生物製藥公司 | 具有化學結合位點之抗原呈現多肽及其使用方法 |
-
2013
- 2013-12-05 EP EP19197120.9A patent/EP3640375A3/en not_active Withdrawn
- 2013-12-05 CA CA2894511A patent/CA2894511C/en active Active
- 2013-12-05 KR KR1020157017981A patent/KR102208505B1/ko not_active Expired - Fee Related
- 2013-12-05 SG SG11201504558TA patent/SG11201504558TA/en unknown
- 2013-12-05 CN CN201811139644.3A patent/CN109324190A/zh active Pending
- 2013-12-05 SG SG10201808463RA patent/SG10201808463RA/en unknown
- 2013-12-05 AU AU2013359907A patent/AU2013359907B2/en not_active Ceased
- 2013-12-05 JP JP2015545835A patent/JP2016500255A/ja not_active Ceased
- 2013-12-05 EP EP13862361.6A patent/EP2931949B1/en active Active
- 2013-12-05 BR BR112015013557-9A patent/BR112015013557B1/pt not_active IP Right Cessation
- 2013-12-05 WO PCT/US2013/073275 patent/WO2014093118A1/en not_active Ceased
- 2013-12-05 CN CN201380071758.8A patent/CN105121715B/zh not_active Expired - Fee Related
- 2013-12-05 US US14/649,176 patent/US10048271B2/en active Active
-
2015
- 2015-05-31 IL IL239096A patent/IL239096B/en active IP Right Grant
-
2018
- 2018-03-14 AU AU2018201812A patent/AU2018201812B2/en not_active Ceased
- 2018-07-25 US US16/044,608 patent/US11226339B2/en active Active
- 2018-11-05 IL IL262785A patent/IL262785B/en active IP Right Grant
-
2019
- 2019-11-05 JP JP2019200491A patent/JP7128792B2/ja active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050009012A1 (en) * | 2001-01-25 | 2005-01-13 | Large Scale Biology Corporation | Cytoplasmic inhibition of gene expression and expression of a foreign protein in a monocot plant by a plant viral vector |
| CN101384621A (zh) * | 2005-11-10 | 2009-03-11 | 受体生物公司 | 产生受体和配体同种型的方法 |
| US20080269070A1 (en) * | 2007-04-27 | 2008-10-30 | Dow Global Technologies, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| CN101688213A (zh) * | 2007-04-27 | 2010-03-31 | 陶氏环球技术公司 | 用于快速筛选微生物宿主以鉴定某些在表达异源蛋白质方面具有改善的产量和/或质量的菌株的方法 |
Non-Patent Citations (2)
| Title |
|---|
| FRANK H BÜTTNER: ""Cell-based assays for high-throughput screening"", 《EXPERT OPIN DRUG DISCOV》 * |
| 许媛媛 等: ""高通量药物筛选模型的研究进展"", 《上海交通大学学报( 医学版)》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3640375A3 (en) | 2020-07-29 |
| SG10201808463RA (en) | 2018-11-29 |
| JP2016500255A (ja) | 2016-01-12 |
| CN105121715A (zh) | 2015-12-02 |
| CA2894511A1 (en) | 2014-06-19 |
| EP2931949A1 (en) | 2015-10-21 |
| US11226339B2 (en) | 2022-01-18 |
| SG11201504558TA (en) | 2015-07-30 |
| BR112015013557A2 (pt) | 2020-01-14 |
| KR20150094674A (ko) | 2015-08-19 |
| AU2013359907B2 (en) | 2018-01-18 |
| JP7128792B2 (ja) | 2022-08-31 |
| IL239096A0 (en) | 2015-07-30 |
| AU2013359907A1 (en) | 2015-06-18 |
| AU2018201812B2 (en) | 2020-09-10 |
| EP2931949A4 (en) | 2016-07-27 |
| US20160011204A1 (en) | 2016-01-14 |
| JP2020043860A (ja) | 2020-03-26 |
| IL262785B (en) | 2020-04-30 |
| IL262785A (en) | 2018-12-31 |
| EP3640375A2 (en) | 2020-04-22 |
| IL239096B (en) | 2019-03-31 |
| EP2931949B1 (en) | 2019-09-18 |
| HK1218144A1 (zh) | 2017-02-03 |
| CA2894511C (en) | 2021-12-07 |
| BR112015013557B1 (pt) | 2021-12-14 |
| KR102208505B1 (ko) | 2021-01-27 |
| WO2014093118A1 (en) | 2014-06-19 |
| US20200011875A1 (en) | 2020-01-09 |
| CN105121715B (zh) | 2018-10-26 |
| US10048271B2 (en) | 2018-08-14 |
| AU2018201812A1 (en) | 2018-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018201812B2 (en) | Methods for high throughput receptor:ligand identification | |
| Dobson et al. | Antigen identification and high-throughput interaction mapping by reprogramming viral entry | |
| CN107995926B (zh) | 嵌合抗原受体和使用方法 | |
| KR20110136783A (ko) | 세포-표면 항원의 면역결합제를 동정하는 방법 | |
| EP4444878A1 (en) | Methods and compositions for discovery of receptor-ligand specificity by engineered cell entry | |
| EP3956362A1 (en) | Bioassay for t-cell co-stimulatory proteins containing fc domains | |
| US20240151731A1 (en) | Membrane protein interaction screening platform based on cell-cell adhesion effects | |
| KR20180064506A (ko) | 게놈-규모 t 세포 활성 어레이 및 그의 사용 방법 | |
| CN114437232A (zh) | 一种细胞表面大分子定量展示系统及其制备方法和用途 | |
| HK1218144B (zh) | 高通量受体:配体鉴定方法 | |
| KR102059866B1 (ko) | 세포-표면 항원의 면역결합제를 동정하는 방법 | |
| Atolia | Empirical Reverse Engineering of Vaccine Neoantigens | |
| CN101712950B (zh) | 可以高效率地检索5-羟色胺6受体配体的可稳定表达ha-5-ht6r的细胞系 | |
| AU2013203478B2 (en) | Methods for identifying immunobinders of cell-surface antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: New York, USA Applicant after: ALBERT EINSTEIN COLLEGE OF MEDICINE, Inc. Address before: New York, USA Applicant before: Kam associates |
|
| CB02 | Change of applicant information | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200324 Address after: New York, USA Applicant after: Albert Einstein Medical College Address before: New York, USA Applicant before: ALBERT EINSTEIN COLLEGE OF MEDICINE, Inc. Effective date of registration: 20200324 Address after: New York, USA Applicant after: Kam associates Address before: New York, USA Applicant before: Albert Einstein College of Medicine, Inc. |
|
| TA01 | Transfer of patent application right | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190212 |
|
| WD01 | Invention patent application deemed withdrawn after publication |